Why Hair Loss Is No Longer Just a DHT Story

For nearly three decades, treating pattern hair loss meant one thing: fight DHT. Every proven treatment lowers it, blocks it, or works around it. That model is not wrong, but recent research has revealed that DHT is only the opening chapter. Beneath it sits a whole biology of dormant stem cells, scalp inflammation, tissue scarring, and the scalp's microbial ecosystem. This is why the pipeline suddenly looks so different, and why the next generation of treatments will do things finasteride never could.

By Radiance360 · Pharmacist-Formulated · 2026

The quick answer

Is hair loss only about DHT?

No. DHT is the primary trigger, but research now shows it sets off a cascade, dormant stem cells, inflammation, fibrosis, and microbiome changes, that also drive the loss.

Why does this matter?

Treatments that only target DHT cannot address these downstream processes, which is why some people keep losing hair despite perfect DHT control.

What are the new mechanisms?

Stem cell dormancy, the PGD2 inflammatory pathway, CXCL12-driven fibrosis, RNA interference, and scalp microbiome dysbiosis.

What should I do now?

Treat DHT with proven tools today, because controlling the trigger remains the foundation everything else builds on.

The Model That Ruled for 30 Years

The DHT model is simple and largely correct. Dihydrotestosterone binds to receptors in genetically sensitive follicles and triggers miniaturisation: each cycle produces a thinner, shorter hair, until the follicle stops producing visible hair.

This gave us two pillars: finasteride reduces DHT production; minoxidil, though it works on blood flow, supports the follicle. The minoxidil vs finasteride guide covers the mechanism the whole field was built on.

The model is valid but incomplete: it explains what starts pattern hair loss, not everything that sustains and worsens it. That gap is what recent research has begun to fill.

Discovery One: The Follicles Are Not Dead, Just Dormant

The most hopeful discovery: follicles in a bald scalp are often not destroyed.

In February 2025, researchers at the University of Virginia reported stem cells persisting in the upper and middle sections of hair follicles even in balding scalp, challenging the assumption that advanced pattern baldness means permanent follicle loss. The cells are still there, in a state of metabolic dormancy, switched off rather than eliminated.

This reframes treatment. If the machinery survives, the aim shifts from slowing loss to reactivating what is dormant, the principle behind stem-cell-activating drugs now in trials, which wake these cells through metabolism rather than touching DHT.

For 30 years we assumed a bald scalp was a graveyard of follicles. The new evidence suggests it is closer to a field lying fallow: the follicles are resting, not gone. That distinction changes what "reversal" could one day mean.

Discovery Two: The PGD2 Inflammatory Pathway

DHT does not act alone. One way it damages follicles is by driving up a molecule called prostaglandin D2, or PGD2.

Research shows PGD2 is significantly elevated in balding areas of the scalp, while beneficial prostaglandins are reduced. PGD2 inhibits hair growth through several routes, including suppressing the Wnt pathway follicles depend on. Work in Cells in 2023 traced how a protein called CXXC5 mediates DHT-induced hair loss through this PGD2 route, connecting the hormone to the inflammation it triggers.

The importance is that PGD2 is a target downstream of DHT. DHT could be well controlled, yet PGD2 inflammation might still suppress growth, one reason some men on finasteride still thin, and why drugs targeting PGD2 are explored as complements to DHT treatment, not replacements.

Discovery Three: Fibrosis and the CXCL12 Loop

One significant recent finding concerns the tissue around the follicle, not the follicle itself.

Single-cell RNA sequencing studies in 2024 and 2025 identified a molecule called CXCL12 as a driver of fibroimmune remodelling in pattern hair loss. As follicles miniaturise, the surrounding tissue undergoes progressive scarring and immune change, with CXCL12 at the centre of this self-reinforcing loop, reprogramming the dermal papilla cells that instruct hair growth and recruiting pro-fibrotic immune cells that impair regeneration.

The exciting part: in lab studies, blocking CXCL12 with a neutralising antibody reversed these changes and promoted regrowth. The research suggests this fibrosis may be reversible rather than permanent, meaning the tissue environment, long thought a dead end, might itself be treatable.

Discoveries Four and Five: RNA Interference and the Microbiome

Two further frontiers show how wide the field has become.

RNA interference takes a different route. Instead of blocking DHT or its receptor, RNAi therapies reduce production of the androgen receptor itself at the genetic level. A candidate from OliX Pharmaceuticals is in early clinical study, cutting androgen receptor expression rather than blocking the hormone.

The scalp microbiome is the newest frontier. The bacteria and fungi on the scalp influence follicle health, and dysbiosis, an imbalance in that community, has emerged as both a biomarker and a possible treatment target. This is why scalp health and dandruff control matter for anyone treating hair loss, explored in the hair care range.

What This Means, and Why DHT Control Still Comes First

The picture emerging is not that DHT was wrong, but that DHT is the first domino, triggering a cascade, dormancy, PGD2 inflammation, CXCL12 fibrosis, microbiome disruption, and each then contributes to hair loss in its own right. This explains the most frustrating experience in treatment: the person who controls DHT well and still loses hair. It also explains why the pipeline now holds more than 100 candidates from over 80 companies. The field is no longer chasing a better DHT blocker; it is targeting the whole cascade.

But this points back to today. Because DHT is the trigger for the whole cascade, controlling it early limits how much downstream damage ever gets set in motion. Proven DHT-focused treatment is not made obsolete by the new biology; it is made more important by it. Starting minoxidil and finasteride early, delivered together in the hair fall solution range at verified concentrations, is the most effective thing you can do to stop the downstream processes taking hold. Future treatments targeting dormancy and fibrosis will work best on scalps where the trigger was controlled early, not left to run for years. For a DHT-free path, the peptide-based options in the Regrow Xpert comparison follow the same principle.

Frequently Asked Questions

What causes hair loss besides DHT?

DHT is the primary trigger, but research shows it sets off other processes that also drive loss: stem cell dormancy, PGD2-driven inflammation, CXCL12-related fibrosis, and scalp microbiome imbalance. These operate downstream of DHT and help explain why some people keep losing hair despite controlling it.

Is hair loss only about DHT?

No. DHT remains the main starting point, but it is now understood as the first step in a larger cascade rather than the whole story. This is why the newest treatments target mechanisms beyond DHT, though controlling DHT remains the foundation of effective treatment today.

Kya hair loss sirf DHT ki wajah se hoti hai?

Nahi. DHT bunyadi trigger hai, lekin research batati hai ke yeh doosre processes bhi shuru kar deta hai: stem cell dormancy, PGD2 inflammation, tissue fibrosis, aur scalp microbiome imbalance. Isi liye kuch log DHT control karne ke bawajood baal khote rehte hain. Lekin DHT ko jaldi control karna aaj bhi sabse zaroori qadam hai.

Kya naye treatments finasteride se behtar hain?

Abhi tak nahi. Naye treatments DHT ke alawa doosre mechanisms ko target karte hain, jo promising hai, lekin zyada tar trials mein hain aur saal door hain. Filhaal DHT ko control karna, jaise minoxidil aur finasteride se, hi sabse zaroori aur proven qadam hai.

To Sum Up

Hair loss is no longer a simple DHT problem. DHT is the trigger, but it sets off a cascade: dormant stem cells that may be reawakened, PGD2 inflammation that suppresses growth, CXCL12 fibrosis that may be reversible, and a scalp microbiome that shapes follicle health. This richer picture is why the pipeline has exploded and why the next generation of treatments will reach places finasteride never could.

But the new biology does not replace the old wisdom; it reinforces it. DHT is the first domino, and controlling it early limits everything that follows. The most powerful thing you can do while these treatments move through trials is protect your follicles now, so there is as much healthy biology as possible for the next breakthrough. The science is finally moving beyond DHT. Your best move today is still to control it.

Hair Fall Solution Collection | Full Hair Care Range | Minoxidil vs Finasteride Guide